KKR Acquires Bushu Pharmaceuticals from BPEA EQT
December 20, 2022
KKR has agreed to acquire Bushu Pharmaceuticals, a leading Japanese pharmaceutical CDMO headquartered in Kawagoe, from the BPEA V Fund (BPEA EQT). Bushu operates four manufacturing facilities across Japan, employs around 1,600 people, and provides contract development and manufacturing services for pharmaceuticals and medical devices; the deal is expected to close in Q1 2023 subject to customary approvals.
- Buyers
- KKR
- Targets
- Bushu Pharmaceuticals
- Sellers
- BPEA V Fund (BPEA EQT)
- Industry
- Pharmaceuticals
- Location
- Saitama, Japan
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Bora Pharmaceuticals Acquires Upsher-Smith Laboratories
August 5, 2025
Pharmaceuticals
Bora Pharmaceuticals completed a 2024 acquisition of Upsher-Smith Laboratories for $210 million and is expanding the Maple Grove, Minnesota manufacturing site with a multi-year buildout. The investment includes installation of a Gerteis Macro-Pactor (operational Q3 2025) and development of 100,000 square feet of shell space to boost oral solid dose (OSD) contract development and manufacturing capabilities.
-
Bain Capital to Acquire Mitsubishi Tanabe Pharma in $3.3B Carve-Out
February 7, 2025
Pharmaceuticals
Bain Capital has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (Tanabe Pharma) in a carve-out transaction from Mitsubishi Chemical Group Corporation. The deal values Tanabe Pharma at approximately 510 billion JPY (~$3.3 billion) and is expected to close in the third quarter of 2025, subject to regulatory clearance and approvals.
-
Shionogi Inc. Acquires Qpex Biopharma, Inc.
June 26, 2023
Pharmaceuticals
Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., entered into a definitive agreement to acquire San Diego-based clinical-stage antimicrobial developer Qpex Biopharma, Inc. The acquisition (upfront $100 million plus up to $40 million in milestones) brings Qpex's investigational beta-lactamase inhibitor xeruborbactam and expands Shionogi's infectious disease R&D capabilities and pipeline.
-
Asahi Kasei Medical to Acquire Bionova Scientific
April 14, 2022
Healthcare Services
Asahi Kasei Medical, through a U.S. subsidiary, has agreed to wholly acquire Bionova Scientific, LLC, a U.S.-based biopharmaceutical CDMO providing contract process development and GMP-compliant contract manufacturing services. The acquisition will add CDMO capabilities to Asahi Kasei Medical’s existing bioprocess business and broaden know-how-driven services for next-generation antibody drugs.
-
KKR Acquires Mitsubishi Corp.-UBS Realty Inc. (MC-UBSR) in Strategic Transaction
March 17, 2022
Real Estate
KKR, through a subsidiary (76KK), will acquire all of the outstanding shares of Mitsubishi Corp.-UBS Realty Inc. (MC-UBSR) in an all-cash transaction valued at JPY230 billion (US$2 billion). Mitsubishi and UBS Asset Management (UBS-AM) are selling MC-UBSR, a leading Japanese real estate asset manager that manages the Tokyo Stock Exchange-listed REITs Japan Metropolitan Fund Investment Corporation (JMF) and Industrial & Infrastructure Fund Investment Corporation (IIF).
-
EQT Acquires Baring Private Equity Asia
March 16, 2022
Financial Services
EQT AB has agreed to acquire Baring Private Equity Asia (BPEA) in a €6.8bn transaction comprising 191.2m new EQT shares and ~€1.5bn–€1.6bn in cash, creating a scaled Pan-Asian active ownership platform rebranded as BPEA EQT Asia. The combination brings BPEA's private equity and real estate capabilities into EQT's global platform, with BPEA CEO Jean Eric Salata to lead the combined Asian business.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.